• Posted

New at RueOne: Up to $8M Financing For a Medical Device Company Focusing on Hypertension

RueOne is offering investors the ability to participate in a financing for a medical device company with a unique product to treat uncontrolled hypertension, a condition that affects 35 million Americans and could represent a $100 Billion market opportunity in the US alone.

The product uses an innovative approach called renal denervation, a procedure to kill nerves around the renal artery to lower hypertension. The Cleveland Clinic has declared renal denervation as a top medical innovation. Until recently, it has been difficult to find the right solution to treat the condition using renal denervation. This is where the company's’ technology comes in.

Use of proceeds is to conduct a post-market CE Mark clinical study in Europe; maintain IND approval with the FDA for the already cleared US Phase I clinical study; and general corporate purposes.

Attractive Time to Enter Renal Denervation Market

What is exciting about this opportunity is that it is a particularly attractive time to invest in a renal denervation company. A well-publicized and costly clinical trial by Medtronic in 2014 went poorly and caused funding and interest to dry up. Based on new promising clinic data and a re-assessment of the Medtronic trial, market participants are once again seeing renewed excitement about the space. The company's’ technology which is different from Medtronic’s approach is showing promising signs of being more precise and therefore more effective. 

Investors who want to find out more about the opportunity can access additional information in our deal room once they undergo a simple registration process. There they’ll find extensive information that can form the basis of their due diligence including:

·       Deal overview

·       Investment summary

·       Additional details on the company and its innovative technology

·       Further discussion of the renal denervation market

·       Background on the Sponsor principals

·       A video of a due diligence Q&A with the deal Sponsor

I invite you to register with RueOne today @ https://login.rueone.com and learn more.

RueOne. Direct Investment made simple.

RueOne Investments, LLC
21 West 46th Street, 16th Floor
New York, NY 10036

info@rueone.com

By accessing this website or any of its pages, you have agreed to be bound by the Platform’s Terms of Use and Privacy Policy. The Platform does not provide investment, legal or tax advice. No communication, through this website or in any other medium, should be construed as a recommendation by RueOne Investments of any securities offering on or off the Platform. Investments displayed on the Platform are intended for accredited investors who are familiar with and are willing to accept the high risk associated with investing in real estate and privately held companies. These investments are not publicly traded and may be illiquid involving an indefinite holding period. These investments are intended for investors who do not have a need for liquidity and can afford to lose a portion or all of their investment. To the fullest extent permissible by law, neither RueOne nor any of its directors, officers, employees, representatives, affiliates or agents shall have any liability whatsoever arising out of any error or incompleteness of fact or opinion in the presentation or publication of the material and communication on the Platform.